Home › Funds › Fulcrum Asset Management LLP › ABT
Fulcrum Asset Management LLP position in ABT
ABBOTT LABORATORIES · Health Care
Fulcrum Asset Management LLP reported holding 81,700 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$8.2M, representing 0.39% of its reported portfolio and ranking #39 among its reported holdings. Fulcrum Asset Management LLP has disclosed ABT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-04 · Source: SEC EDGAR Form 13F-HR
How Fulcrum Asset Management LLP's ABT position evolved
Fulcrum Asset Management LLP first disclosed a stake in ABT in Q2 2026 at 63,409 shares (US$5.9M). The position peaked in Q3 2026 at 81,700 shares, worth US$8.2M. Across 2 filings, Fulcrum Asset Management LLP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 81,700 shares valued at US$8.2M — an increase of 18,291 shares quarter over quarter.. Notable position changes include a 29% increase in Q3 2026 (shares rose 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 63.41K | $5.88M | New |
| Q3 2026 | 81.70K | $8.25M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on Fulcrum Asset Management LLP
FAQ
How long has Fulcrum Asset Management LLP held ABT?
Fulcrum Asset Management LLP has disclosed ABT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Fulcrum Asset Management LLP's current position in ABT?
As of Q3 2026, Fulcrum Asset Management LLP holds 81.70K shares of ABT (ABBOTT LABORATORIES), valued at $8.25M, representing 0.39% of its reported portfolio and ranking #39.
Has Fulcrum Asset Management LLP been buying or selling ABT?
In the latest 13F filing (Q3 2026), Fulcrum Asset Management LLP increased its position in ABT. The position peaked in Q3 2026 at 81.70K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.